Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Thursday, October 1, 2026

⚡ Executive Takeaway

The most serious competitor to Lilly's best obesity drug is now another Lilly asset. In one Wednesday the company showed an amylin stacked on tirzepatide beating tirzepatide itself, a day after its triple agonist reset the efficacy ceiling, and then closed the evening with clean cardiovascular paper for its oral. The unit of competition in this market has quietly stopped being the molecule and become the stack: an incretin backbone plus a second mechanism, tuned across dose, tolerability, and eventually price, inside a single portfolio. That changes what everyone else is building toward. Beating Zepbound is no longer the bar; the bar is fielding a portfolio that can trade depth for tolerability at multiple price points, and only two companies are credibly assembling one. Here is the detail worth sitting with: the market sold Lilly 2.3% on the strongest data day this category has ever produced. When evidence that good cannot move the stock, the argument has moved elsewhere, to pricing power, and the pricing lattice got finished the same afternoon in a CMS final rule. Friday we grade the delivery layer week.

The full arm tables, the GLOBE parameters, and the day's movers, all below. 👉 Read Full Analysis

🧪 Obesity and Diabetes

Lilly stacked an amylin on tirzepatide and beat its own best injectable. LLY

EloraTZP, pairing the selective amylin agonist eloralintide with tirzepatide, cut body weight up to 23.3% over 48 weeks versus 14.8% for tirzepatide 15 mg alone in a Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, per Lilly's release; Endpoints News called it the best weight loss yet reported in this population. The subtler result sits in the middle arms: 19.4% and 19.9% weight loss on only 5 or 10 mg of tirzepatide, meaning the amylin buys depth while sparing incretin dose. The cost was tolerability: discontinuations for adverse events ran 10.8% to 27.0% across combination arms against 2.9% on tirzepatide alone (placebo, notably, was 16.7%). Phase 3 of a single combined formulation starts by the end of 2026 with a reworked dose escalation. LLY closed at 1157.08, down 2.3%, in the first session after the retatrutide release and on the same day as both of Wednesday's readouts; we note the session's context and assign no single cause.

❤️ The Oral Front

Foundayo passed the cardiovascular test, and the fine print is where the value sits. LLY

ACHIEVE-4, the largest and longest Phase 3 of Lilly's oral GLP-1, met its primary endpoint: noninferior cardiovascular safety versus titrated insulin glargine (hazard ratio 0.84) in 2,749 adults with type 2 diabetes, obesity or overweight, and elevated cardiovascular risk, per Lilly's release, which crossed Wednesday evening ahead of the Thursday Milan presentation, the third time this congress a sponsor has released the night before. Superiority was not met (p=0.336), but preplanned analyses showed 53% lower cardiovascular death and 57% lower all cause mortality. Read those with discipline: open label, against insulin, they describe performance versus an older standard of care, not proof of protection. For a launched oral heading deeper into primary care, that is still exactly the paper the sales force wanted; the dedicated ATTAIN-OUTCOMES trial is where a claim could someday come from.

💊 The Delivery Layer

The pill held the line: switchers kept losing weight after leaving the needle. NVO

Novo's OCTANE analysis, presented Wednesday in Milan, answered the question payers have been asking since the Wegovy pill launched: patients who switched from injectable semaglutide or tirzepatide lost a further 4.1% of body weight over three months, with 40.7% losing at least another 5%, per Novo's release. The evidence is thin by design, a retrospective cohort of 194 patients from the Ro telehealth platform with no comparator, but it is the first real world signal that leaving the needle does not mean giving back the loss, and the pill is now launched in the US, UAE, UK, and Germany. Novo's other releases addressed the quality of weight loss: a CagriSema brain imaging study showing reduced food cravings at 52 weeks, and a REIMAGINE 1 MRI sub study showing significant reductions in abdominal, liver, and pancreatic fat, which also puts a Novo release behind part of the body composition dataset we flagged as unverifiable on Tuesday.

🏛️ Policy

International reference pricing now touches every federal drug channel.

CMS finalized the GLOBE rule Wednesday: a mandatory Medicare Part B payment model benchmarking rebates to international prices, in randomly selected regions covering about 25% of Original Medicare, from January 1, 2027 through March 2032, per the CMS release. The final rule added exclusions after comment: orphan only drugs, plasma derived products, certain cell and gene therapies, and marketed biosimilars. Endpoints News reported the projected savings fell from $11.9 billion in the proposal to $440 million in the final, a collapse consistent with those exclusions, though we could not independently confirm the figure Wednesday night. The same day was the GENEROUS Medicaid signing deadline: 40 states plus Puerto Rico had signed as of CMS's September 18 update, with every state having applied; the final count had not been published by Wednesday evening. Between Part B, Medicaid, and the tariff deals, the most favored nation architecture is now complete across channels.

🫀 Cardio and Fibrosis

BMS banked a pediatric first and a liver question on the same day. BMY | CTNM

The FDA expanded Camzyos (mavacamten) to patients 12 to under 18 weighing at least 30 kg, the first approved therapy for pediatric obstructive hypertrophic cardiomyopathy, on the SCOUT-HCM trial, where the drug cut the Valsalva outflow gradient 48.0 mm Hg more than placebo in 44 adolescents, per BMS's release at 5:32 pm ET. The other BMS story cut the other way: per BioPharma Dive, a trial amendment disclosed one patient death from liver injury, with causality unclear, in the Phase 3 extension of admilparant, its LPA1 fibrosis drug, with enhanced liver monitoring added. Contineum, developing a drug in the same class, slid Tuesday on the readacross and closed up 16.7% Wednesday at 13.42 after analysts called the concern overdone. Full admilparant results are due by the end of 2026; the first new fibrosis class in a decade now reads out under a liver question.

🩸 Diagnostics

Abbott put a blood test for colorectal cancer screening on the market. ABT

Abbott launched SimpleScreen CRC, the FDA approved blood test developed by Freenome, for average risk adults 45 and older, with Medicare Part B coverage at no out of pocket cost, per Abbott's release. The pivotal numbers, from more than 48,000 asymptomatic adults: 81.1% sensitivity for colorectal cancer, 63.5% for stage I, 90.4% specificity, and 13.7% sensitivity for advanced precancerous lesions, the figure that keeps colonoscopy and stool testing first line. The launch matters less as a performance story than as a distribution one: a blood draw reaches the roughly 60 million screening eligible adults who decline the preferred options, and it puts Abbott on both sides of the modality question, selling the stool based Cologuard Plus and the blood based alternative from the same bag.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

Lilly spent one Wednesday turning the obesity race into an argument with itself, and Washington spent the same afternoon finishing the pricing lattice around it. Thursday grades the Milan reception; Friday grades the delivery layer week. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →